Back to Journals » Cancer Management and Research » Volume 11

MicroRNA-21 and microRNA-30c as diagnostic biomarkers for prostate cancer: a meta-analysis

Authors Zhou H, Zhu X

Received 28 September 2018

Accepted for publication 23 January 2019

Published 6 March 2019 Volume 2019:11 Pages 2039—2050


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Dr Beicheng Sun

Hongxing Zhou,1 Xuming Zhu2

1Department of Clinical Laboratory, Changzhou No.2 People’s Hospital affiliated to Nanjing Medical University, Changzhou, Jiangsu Province, China; 2Department of Clinical Laboratory, Wuxi People’s Hospital affiliated to Nanjing Medical University, Wuxi, Jiangsu Province, China

Background: Prostate cancer (PCa) is the second leading cause of cancer death in men. Several articles have reported that microRNA-21 (miR-21) and microRNA-30c (miR-30c) have diagnostic values for PCa, but the results are inconclusive. In order to precisely assess the diagnostic values of miR-21 and miR-30c for PCa, this meta-analysis is performed.
Methods: Articles were searched in the databases of PubMed, Embase, and Web of Knowledge (search date: September 6, 2018). Studies were included if they were designed to evaluate the diagnostic performance of miR-21 or miR-30c for PCa. Using Stata 12.0 and Meta-Disc 1.4, the pooled sensitivity (SEN), specificity (SPE), positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR), and area under curve (AUC) of the summary receiver-operating characteristic (SROC) curve with the corresponding 95% CI were calculated.
Results: Overall, ten studies (six studies for miR-21 and four for miR-30c) involving1,371 participants were included in this meta-analysis. For miR-21, the pooled SEN and SPE were, respectively, 0.91 (95% CI: 0.87–0.94) and 0.88 (95% CI: 0.82–0.93), the pooled PLR and NLR were, respectively, 7.74 (95% CI: 4.81–12.47), 0.1 (95% CI: 0.06–0.15), the DOR was 77.64 (95% CI: 34.64–174.02), AUC of SROC was 0.95 (95% CI: 0.93–0.97). For miR-30c, the pooled SEN and SPE were, respectively, 0.74 (95% CI: 0.65–0.81) and 0.78 (95% CI: 0.72–0.83), the pooled PLR and NLR were, respectively, 3.39 (95% CI: 2.69–4.26), and 0.34 (95% CI: 0.26–0.44), the DOR was 10.06 (95% CI: 6.96–14.55), and AUC of SROC was 0.83 (95% CI: 0.79–0.86).
Conclusion: For PCa, miR-21 is a good diagnostic biomarker and miR-30c is a moderate diagnostic biomarker.

Keywords: microRNA-21, microRNA-30c, prostate cancer, meta-analysis

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]